178 related articles for article (PubMed ID: 25700648)
1. [Modern disease-modifying antirheumatic drugs].
Müller-Ladner U; Richter K; Tarner IH
Internist (Berl); 2015 Mar; 56(3):307-14. PubMed ID: 25700648
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
3. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.
Kristensen LE; Saxne T; Nilsson JA; Geborek P
Arthritis Res Ther; 2006; 8(6):R174. PubMed ID: 17121678
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
5. [Biologics in rheumatology].
Wagner U
Internist (Berl); 2019 Oct; 60(10):1036-1042. PubMed ID: 31485714
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
[TBL] [Abstract][Full Text] [Related]
7. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine.
Umićević Mirkov M; Coenen MJ
Pharmacogenomics; 2013 Mar; 14(4):425-44. PubMed ID: 23438889
[TBL] [Abstract][Full Text] [Related]
9. Combination Therapy With and Without Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Trials.
Graudal N; Hubeck-Graudal T; Faurschou M; Baslund B; Jürgens G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1487-95. PubMed ID: 25989246
[TBL] [Abstract][Full Text] [Related]
10. [Recent progress in clinical trials for rheumatic diseases].
Tanaka Y
Nihon Rinsho; 2009 Mar; 67(3):619-25. PubMed ID: 19280942
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach.
Devine EB; Alfonso-Cristancho R; Sullivan SD
Pharmacotherapy; 2011 Jan; 31(1):39-51. PubMed ID: 21182357
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab for rheumatology: development and its potential place in therapy.
Koenders MI; van den Berg WB
Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
[TBL] [Abstract][Full Text] [Related]
13. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis.
Mandema JW; Salinger DH; Baumgartner SW; Gibbs MA
Clin Pharmacol Ther; 2011 Dec; 90(6):828-35. PubMed ID: 22048227
[TBL] [Abstract][Full Text] [Related]
14. Current concepts in the management of rheumatoid arthritis.
Tanaka Y
Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
[TBL] [Abstract][Full Text] [Related]
15. To stop the erosion of hope: the DMARD category and the place of semantics in modern rheumatology.
Buer JK
Inflammopharmacology; 2017 Apr; 25(2):185-190. PubMed ID: 28194545
[TBL] [Abstract][Full Text] [Related]
16. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
17. Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.
Callhoff J; Weiß A; Zink A; Listing J
Rheumatology (Oxford); 2013 Dec; 52(12):2127-35. PubMed ID: 23946435
[TBL] [Abstract][Full Text] [Related]
18. Coverage inequalities of new therapies for rheumatoid arthritis in a managed care setting.
Gallup E
Manag Care Interface; 2001 Jul; 14(7):52-4, 57-8, 69. PubMed ID: 11481817
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
Goldblatt F; Isenberg DA
Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
[TBL] [Abstract][Full Text] [Related]
20. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
